CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: February 28, 2014
Result type: Reports
Project Number: SR0373-000
Product Line: Reimbursement Review

Generic Name: Ranibizumab

Brand Name: Lucentis

Manufacturer: Novartis Pharmaceuticals Canada Inc.

Therapeutic Area: Myopic choroidal neovascularisation

Indications: Choroidal neovascularisation, myopic

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: February 19, 2015

Recommendation Type: List with criteria/condition